BCL2 and B-cell chronic lymphocytic leukemia: The introduction of treatment regimens including chemo-immunotherapy have significantly improved response to therapy for patients with chronic lymphocytic leukaemia (CLL); however, recent advances targeting the ability of receptor signalling to maintain cell survival, and the anti-apoptotic function of BCL2 are proving highly successful, highlighting the key role of these pathways in CLL [1].